FierceBiotechFierceBiotechResearchFierceBiotechITFierceVaccinesFiercePharmaFiercePharmaManufacturing   FierceHealthcare

Free Newsletter

About | View Sample | Privacy

Onyx CEO to retire

Hollings C. Renton, CEO of Onyx Pharmaceuticals, announced plans to retire next year. He will remain chairman of the board of directors. The company has initiated a search for his successor. Onyx has promoted Laura A. Brege to the newly-created position of executive vice president and CEO and Randy A. Kelley to senior vice president of sales and marketing. Onyx, together with Bayer, developed Nexavar, an approved live cancer therapy that made waves at this year's ASCO conference.

- see this release from Onyx

Related Articles:
Bayer, Onyx seek new Nexavar approval. Report
Bayer, Onyx tout Nexavar data. Report
Bayer, Onyx announce disappointing Nexavar results. Report

Bookmark and Share
Get Your FREE FierceBiotech Email Newsletter:
Be the first to comment
More stories about Onyx Pharmaceuticals   sales and marketing   Cancer   Bayer Schering   Nexavar   ASCO  

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

To combat spam, please enter the code in the image.